Our Investors

Investing in

PredictImmune

BGF and Cambridge Innovation Capital joined existing investors Parkwalk, Wren Capital and Cambridge Enterprise, in PredictImmune’s Series B funding round, which completed in July 2019. The £10m investment, was a follow on to the Series A equity financing of £4.7m and has cemented PredictImmune’s solid financial position, enabling the Company to focus on continued global commercial expansion and expand its horizons in terms of product development.

Information for Patients

Information for Clinicians

Order a PredictSURE™ test